MTEX · XBRL financial data

Mannatech financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MTEX's year ends in late December)

In thousands of dollars	Q3 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	34,114	32,594	32,694*	29,393	27,740	31,725	29,008*	26,563	29,161	26,635*	24,917	26,650
Cost of revenue	7,413	7,004	8,048*	6,296	6,363	8,105	5,643*	6,827	6,890	6,584*	6,056	6,164
Gross profit	26,701	25,590	24,646*	23,097	21,377	23,620	23,365*	19,736	22,271	20,051*	18,861	20,486
Research and development	—	—	year only	—	—	—	year only	—	—	year only	—	—
Selling, general and administrative	—	—	—	—	—	9,840	10,429*	10,016	9,072	9,793*	9,282	8,976
General and administrative	6,416	7,257	10,525*	10,176	10,860	9,840	10,429*	10,016	—	—	—	—
Total operating expenses	25,988	26,544	25,541*	22,277	22,520	22,733	22,501*	20,569	20,264	20,208*	19,041	19,488
Operating income (loss)	713	(954)	(895)*	820	(1,143)	887	864*	(833)	2,007	(157)*	(180)	998
Interest expense	—	—	—	—	—	109	83*	73	104	127*	104	117
Other income (expense)	333	150	(973)*	871	1,120	(1,495)	2,095*	(418)	611	494*	1,395	284
Income tax expense (benefit)	466	291	(105)*	529	496	(389)	614*	206	590	11,505*	161	150
Net income (loss)	604	(1,105)	(1,756)*	1,180	(624)	(328)	2,262*	(1,530)	1,924	(11,295)*	950	1,015
Earnings per share, basic USD per share	0.32	(0.59)	—	0.63	(0.33)	(0.17)	1.20*	(0.80)	1.01	(5.94)*	0.49	0.53
Earnings per share, diluted USD per share	0.32	(0.59)	—	0.63	(0.33)	(0.17)	1.20*	(0.80)	1.01	(5.94)*	0.49	0.53
Weighted average shares, basic thousands of shares	1,872	1,870	—	1,884	1,885	1,885	1,886*	1,901	1,901	1,901*	1,929	1,930
Weighted average shares, diluted thousands of shares	1,891	1,870	—	1,884	1,885	1,885	1,886*	1,901	1,901	1,901*	1,931	1,930

Balance sheet

CSV

Fiscal quarters (MTEX's year ends in late December)

In thousands of dollars	Q3 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	13,682	9,374	7,731	7,911	9,196	12,150	11,396	9,323	7,141	6,185	7,013	6,034
Accounts receivable	133	645	91	320	99	22	19	102	38	1	10	137
Inventory	15,320	15,838	14,535	13,679	13,155	11,660	10,405	11,820	11,128	10,123	9,674	9,593
Prepaid and other current assets	3,402	2,183	1,774	3,146	2,214	2,291	1,755	3,292	1,587	1,701	2,481	2,009
Total current assets	36,455	31,252	27,664	28,280	27,928	28,700	26,121	26,545	22,085	20,576	21,200	19,412
Property and equipment, net	—	—	4,147	—	—	—	2,858	—	3,232	2,227	—	—
Right-of-use asset	—	—	3,300	3,104	2,807	2,532	2,094	1,963	3,753	3,292	2,836	2,515
Total assets	50,720	45,399	41,206	41,058	39,915	40,572	36,056	36,669	33,920	29,993	29,883	27,469
Accounts payable	5,663	5,825	4,010	4,882	3,454	3,580	2,070	4,373	4,005	2,410	2,877	3,671
Accrued liabilities	6,990	6,930	6,779	5,899	5,965	4,803	3,832	4,307	3,281	3,128	3,263	2,939
Total current liabilities	31,253	28,242	25,780	26,147	23,961	22,952	20,896	22,576	19,503	18,735	19,468	16,865
Lease liability, non-current	—	—	2,600	2,242	1,975	1,787	1,576	1,548	2,702	2,253	1,850	1,474
Total liabilities	36,868	33,757	30,722	30,613	31,716	30,573	27,442	29,084	26,970	35,216	35,437	32,439
Retained earnings (accumulated deficit)	1,915	437	(1,301)	(121)	(745)	(1,073)	1,189	(341)	(2,729)	(14,024)	(13,074)	(12,059)
Total stockholders' equity	13,852	11,642	10,484	10,445	8,199	9,999	8,614	7,585	6,950	(5,223)	(5,554)	(4,970)
Total liabilities and equity	50,720	45,399	41,206	41,058	39,915	40,572	36,056	36,669	33,920	29,993	29,883	27,469
Common shares outstanding (cover page) thousands of shares	1,872	1,865	1,860	1,885	1,885	1,885	1,901	1,901	1,901	1,930	1,930	1,930

Cash flows

CSV

Fiscal quarters (MTEX's year ends in late December)

In thousands of dollars	Q3 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	604	(1,105)	(1,756)*	1,180	(624)	(328)	2,262*	(1,530)	1,924	(11,295)*	950	1,015
Stock-based compensation	234	17*	19*	212	34*	23*	22*	263	(74)*	32*	274	54*
Depreciation and amortization	387	387	404*	416	400	400	360*	293	261*	260*	261	259*
Net cash from operating activities	1,351	(2,687)*	(1,321)*	1,874	(2,666)*	3,272*	(219)*	(1,368)	2,412*	(289)*	1,126	(792)*
Purchases of property and equipment	104	250*	208*	61	82*	260*	(106)*	489	548*	174*	129	10*
Net cash from investing activities	(104)	(250)*	(208)*	(61)	(82)*	(260)*	118*	(489)	(548)*	(174)*	(129)	(10)*
Share repurchases	0	98*	0*	—	—	0*	0*	—	—	—	—	—
Dividends paid	375	373*	0*	0	0*	0*	0*	—	—	—	—	—
Net cash from financing activities	(558)	(722)*	(274)*	(250)	3,359*	(243)*	(905)*	(166)	(73)*	(242)*	(126)	228*
Net change in cash	(106)	(4,319)*	(300)*	155	1,268*	2,914*	(1,209)*	(2,072)	1,245*	(961)*	404	(898)*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.